title: [Intra-arterial infusion chemotherapy for advanced or recurrent breast cancers].
abstract: Ideally, in preoperative intra-arterial infusion chemotherapy (regarding advanced breast cancer) is to obtain the most significant effects concerning histological features. Intra-arterial infusion chemotherapy using epirubicin (EPI), used in conjunction with daily doses of 1,200 mg medroxyprogesterone acetate (MPA), have recently been performed. This procedure has shown remarkable histological effects in the metastatic lymph nodes as well as in the primary lesions. These results were especially remarkable in the patients who were administered MPA (daily) two weeks prior to EPI infusion. These patients showed a complete disappearance of tumor cells. The results were interesting in view of the mechanism of action. Intra-arterial infusion chemotherapy combined with MPA may also be valuable in treating metastatic liver tumors and recurrent lesions in the regional lymph nodes such as supraclavicular tumors. A high response rate was obtained in the chemo-endocrine therapy when combined with MPA as a pretreatment. Thus, MPA may be expected to be available as a systemic therapy, too. In the future, a new development in the field of intra-arterial infusion chemotherapy may be achieved by utilizing a combination of angiogenesis inhibitors and peripheral blood stem cell transplantation.
authors.affiliation: First Dept. of Surgery, Sapporo Medical University School of Medicine.
authors.forename: M
authors.initials: M
authors.lastname: Okazaki
authors.forename: A
authors.initials: A
authors.lastname: Okazaki
authors.forename: H
authors.initials: H
authors.lastname: Masuoka
authors.forename: K
authors.initials: K
authors.lastname: Toda
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: Y
authors.initials: Y
authors.lastname: Okazaki
authors.forename: K
authors.initials: K
authors.lastname: Asaishi
authors.forename: K
authors.initials: K
authors.lastname: Hirata
authors.forename: E
authors.initials: E
authors.lastname: Narimatsu
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008207:Lymphatic Metastasis; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012074:Remission Induction
chemical_list: D015251:Epirubicin; D004317:Doxorubicin; D017258:Medroxyprogesterone Acetate; C027260:pirarubicin